Cullinan Therapeutics, Inc.
CGEM
$7.77
$0.070.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -17.47% | 3.49% | -13.14% | -56.06% | 39.25% |
| Total Depreciation and Amortization | 1.32% | -1.30% | 1.32% | -1.30% | -3.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.98% | -33.86% | 43.96% | 106.96% | -55.57% |
| Change in Net Operating Assets | 161.73% | 260.45% | 80.56% | -278.37% | 1,928.73% |
| Cash from Operations | -7.28% | 5.93% | 5.11% | -110.95% | 46.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.69% | 110.74% | -1,528.77% | -74.83% | 219.81% |
| Cash from Investing | -19.69% | 110.74% | -1,528.77% | -74.83% | 219.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -20.14% | -99.26% | 24,415.02% | 337.50% | 121.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 82.70% | -- | -- | -- |
| Cash from Financing | 19.40% | -99.49% | 24,065.53% | 337.50% | 121.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -47.50% | -131.71% | 268.52% | -172.07% | 143.63% |